• English
  • Korean
  • Chinese
表紙
市場調査レポート - 63236

世界の幹細胞市場

Global Markets for Stem Cells

発行 BCC Research
出版日 ページ情報 英文 142 pages
電子版即納可
価格
世界の幹細胞市場 Global Markets for Stem Cells
出版日: 2012年07月02日 ページ情報: 英文 142 pages
担当者のコメント
米国の調査会社BCC Research社の発行です。前回の発行は2008年でしたので4年ぶりの改訂になります。治療法概要から特許、市場状況、参入企業等を包括的に纏めています。
概要

世界の幹細胞製品市場は、2011年に38億米ドルとなりました。同市場は2011年から2016年の期間中、CAGR11.7%で拡大し、2012年におよそ43億米ドル、2016年までに66億米ドルへ達すると予測されています。米国および欧州の幹細胞製品市場は、2011年にそれぞれ13億米ドル、8億7200万米ドルとなりました。今後の米国および欧州市場はCAGR11.5%、CAGR10.9で拡大し、市場規模は2016年までにそれぞれ23億米ドル、15億米ドルへ達すると予測されています。

当レポートでは、世界の幹細胞市場について調査し、幹細胞研究の見通し、主要国・地域における現在の市場規模と成長率、幹細胞を支える重要な技術のレビュー、幹細胞産業の性質と構造の分析、近年のM&A活動を含む主要企業のプロファイル、および国・主要治療分野別による今後5ヵ年の市場予測などを提供しており、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 サマリー

  • 定義
  • アプリケーション
  • 研究・商業化
  • 市場

第3章 概要

  • 細胞
  • 幹細胞

第4章 幹細胞研究

  • 歴史
  • 細胞ベースの治療
  • 幹細胞研究の規制
  • 幹細胞研究・製造の実用性

第5章 幹細胞のアプリケーション

  • 再生医療
  • 現在の幹細胞治療アプリケーション

第6章 幹細胞の特許

  • 特許の一般的背景
  • 幹細胞の特許
  • 各国の政策

第7章 幹細胞市場

  • 幹細胞市場
  • 市場機会:治療クラス別
  • 地域・国別の市場分析

第8章 企業プロファイル

第9章 付録1:用語

第10章 付録2:注目の幹細胞研究特許

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

REPORT HIGHLIGHTS

The global market for stem cell products was $3.8 billion in 2011. This market is expected to reach nearly $4.3 billion in 2012 and $6.6 billion by 2016, increasing at a compound annual growth rate (CAGR) of 11.7% from 2011 to 2016.

The American market for stem cell products was $1.3 billion in 2011. This sector is expected to rise at a CAGR of 11.5% and reach nearly $2.3 billion by 2016.

The European market for stem cell products was $872 million in 2011 and is expected to reach nearly $1.5 billion by 2016, a CAGR of 10.9%.

image1

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for prescription drug products. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2016; these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the stem cell-related drug market. The wider economic environment is also taken into account.

The report examines strategies employed by companies specializing in this field to meet the challenges of a competitive and fast-growing market.

REASONS FOR DOING THE STUDY

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced a number of significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its practical applications so far, evaluate the participating companies and look to its future.

SCOPE OF REPORT

This report discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting stem cells are reviewed, and the nature and structure of the stem cell industry is discussed with profiles of the leading companies, including recent M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

MARKET ANALYSES AND FORECASTS

Market figures are based on revenues at the manufacturer level and are projected at 2012-dollar value without attempting to predict the effect of inflation/deflation. Therapeutic categories quantified and forecast include cancer, CNS diseases, infections and cardiovascular. Major country markets in three regions - Americas, Europe and Asia - are analyzed and forecast, with a summary for the rest of the world.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Primary research includes interviews with leading individuals in stem cell companies and industry associations. Primary sources of published data include company annual reports, SEC filings, and government and industry publications. Secondary sources consist of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically assessed by BCC.

INTENDED AUDIENCE

This report is designed to satisfy the information needs of a wide variety of individuals involved in the pharmaceutical marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However it is also aimed at managers and executives in marketing, research, planning and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.

INFORMATION SOURCES

Sources of information included marketing strategists, industry executives, government agencies and regulatory bodies, and surveys of physicians and pharmacists. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also reviewed.

ANALYST CREDENTIALS

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the stem cell marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.

Table of Contents

Chapter- 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • MARKET ANALYSES AND FORECASTS
  • METHODOLOGY
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

Chapter- 2: SUMMARY

  • DEFINITIONS
  • APPLICATIONS
  • RESEARCH AND COMMERCIALIZATION
  • MARKET

Chapter- 3: OVERVIEW

  • CELLS
  • STEM CELLS

Chapter- 4: STEM CELL RESEARCH

  • HISTORY
  • CELL-BASED THERAPEUTICS
  • REGULATION OF STEM CELL RESEARCH
  • PRACTICALITIES OF STEM CELL RESEARCH AND PRODUCTION

Chapter- 5: STEM CELL APPLICATIONS

  • REGENERATIVE MEDICINE
  • CURRENT APPLICATIONS OF STEM CELL THERAPY

Chapter- 6: STEM CELL PATENTS

  • GENERAL BACKGROUND ON PATENTS
  • STEM CELL PATENTS
  • INDIVIDUAL COUNTRY POLICIES

Chapter- 7: STEM CELL MARKETS

  • MARKETS FOR STEM CELLS
  • MARKET OPPORTUNITIES BY THERAPEUTIC CLASS
  • REGIONAL AND NATIONAL MARKET ANALYSIS

Chapter- 8: COMPANY PROFILES

  • 3DM
  • AASTROM BIOSCIENCES, INC.
  • ADVANCED CELL TECHNOLOGY, INC.
  • ALDAGEN, INC.
  • ANGIOBLAST SYSTEMS
  • ARTERIOCYTE
  • ATHERSYS INC.
  • BEIKE BIOTECHNOLOGY CO., LTD.
  • BioE
  • BIOHEART, INC.
  • BIOTIME, INC.
  • BRAINSTORM CELL THERAPEUTICS INC.
  • CAPRICOR, INC.
  • CARDIO3 BIOSCIENCES
  • CELLARTIS AB
  • CELLERANT THERAPEUTICS, INC.
  • CELLERIX SA
  • CELLULAR DYNAMICS INTERNATIONAL
  • CYTORI THERAPEUTICS, INC.
  • EPISTEM LTD.
  • FORTICELL BIOSCIENCE, INC.
  • GAMIDA CELL, LTD.
  • GLOBALSTEM
  • HYBRID ORGAN GMBH
  • INTELLICELL BIOSCIENCES, INC.
  • INTERNATIONAL STEM CELL CORPORATION
  • JUVENTAS THERAPEUTICS, INC.
  • MEDISTEM INC.
  • MESOBLAST LTD.
  • NEOSTEM, INC.
  • NEURALSTEM
  • NEUROGENERATION
  • OSIRIS THERAPEUTICS, INC.
  • PHARMASTEM THERAPEUTICS, INC.
  • PLUREON CORPORATION
  • PRIMEGEN BIOTECH, LLC
  • RENEURON GROUP
  • RHINOCYTE INC.
  • STEM CELLS INC.
  • STEMCELL TECHNOLOGIES SARL
  • STEM CELL THERAPEUTICS CORP.
  • STEMEDICA CELL TECHNOLOGIES, INC.
  • STEMINA BIOMARKER DISCOVERY INC.
  • STEMPEUTICS RESEARCH PVT. LTD.
  • TIGENIX NV
  • TRISTEM CORPORATION
  • VERASTEM, INC.
  • VERISTEM TECHNOLOGIES
  • VIACYTE
  • VITRO DIAGNOSTICS, INC.
  • WICELL RESEARCH INSTITUTE
  • XPAND BIOTECHNOLOGY BV

Chapter- 9: APPENDIX 1: GLOSSARY

Chapter- 10: APPENDIX 2: SIGNIFICANT STEM CELL RESEARCH PATENTS

  • Table 59 : SIGNIFICANT STEM CELL RESEARCH PATENTS

List of Tables

  • Summary Table : GLOBAL STEM CELL MARKET AND FORECASTS, THROUGH 2016
  • Table 1 : COUNTRIES ENGAGED IN THE ISCBI PROGRAM
  • Table 2 : IPS-RELATED PATENTS (YAMANAKA, 2011)
  • Table 3 : CLASSIFICATION OF STEM CELL PATENTS
  • Table 4 : HEALTHCARE SYSTEMS OF DIFFERENT COUNTRIES
  • Table 5 : EXAMPLES OF COMPANIES DEVELOPING STEM CELL THERAPIES FOR CVD
  • Table 6 : STATISTICS FOR SCI WORLDWIDE, 2011
  • Table 7 : NEURODEGENERATIVE DISEASES WORLDWIDE, 2011
  • Table 8 : STATISTICS FOR DIABETES IN THE U.S., 2010
  • Table 9 : GLOBAL MARKET FOR DIABETES MELLITUS, TREATMENTS AND DEVICES, THROUGH 2016
  • Table 10 : GLOBAL STEM CELL MARKET, THROUGH 2016
  • Table 11 : STEM CELL MARKET: AMERICAS, HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 12 : POTENTIAL U.S. PATIENT POPULATIONS FOR CELL-BASED THERAPIES
  • Table 13 : U.S. STEM CELL THERAPY MARKET: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 14 : U.S. STEM CELL RESEARCH AND SERVICES MARKET: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 15 : U.S. STEM CELL CORD BLOOD SERVICES MARKET: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 16 : CANADIAN STEM CELL THERAPY MARKET: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 17 : CANADIAN STEM CELL RESEARCH AND SERVICES MARKET: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 18 : CANADIAN STEM CELL CORD BLOOD SERVICES MARKET: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 19 : BRAZIL STEM CELL THERAPY MARKET: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 20 : BRAZIL STEM CELL RESEARCH AND SERVICES MARKET: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 21 : BRAZIL STEM CELL CORD BLOOD SERVICES MARKET: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 22 : MEXICO STEM CELL THERAPY MARKET: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 23 : MEXICO STEM CELL CORD BLOOD SERVICES MARKET: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 24 : STEM CELL MARKET: EUROPE, HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 25 : STATISTICS FOR CVD IN EUROPE, 2011
  • Table 26 : RATE OF DEATH FROM HEART DISEASE IN DIFFERENT EUROPEAN COUNTRIES, 2011
  • Table 27 : STATISTICS FOR CNS DISORDERS AND INJURIES IN EUROPE, 2011
  • Table 28 : STATISTICS FOR SCI AND PARKINSON'S DISEASE IN DIFFERENT EUROPEAN COUNTRIES, 2011
  • Table 29 : PREVALENCE OF DIABETIC PATIENTS IN DIFFERENT EUROPEAN COUNTRIES, 2010
  • Table 30 : STEM CELL THERAPY MARKET IN FRANCE: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 31 : STEM CELL RESEARCH AND SERVICES MARKET IN FRANCE: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 32 : STEM CELL CORD BLOOD SERVICES MARKET IN FRANCE: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 33 : STEM CELL THERAPY MARKET IN GERMANY: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 34 : STEM CELL RESEARCH AND SERVICES MARKET IN GERMANY: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 35 : STEM CELL CORD BLOOD SERVICES MARKET IN GERMANY: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 36 : STEM CELL THERAPY MARKET IN ITALY: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 37 : STEM CELL RESEARCH AND SERVICES MARKET IN ITALY: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 38 : STEM CELL CORD BLOOD SERVICES MARKET IN ITALY: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 39 : STEM CELL THERAPY MARKET IN SPAIN: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 40 : STEM CELL RESEARCH AND SERVICES MARKET IN SPAIN: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 41 : STEM CELL CORD BLOOD SERVICES MARKET IN SPAIN: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 42 : STEM CELL THERAPY MARKET IN U.K.: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 43 : STEM CELL RESEARCH AND SERVICES MARKET IN U.K.: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 44 : STEM CELL CORD BLOOD SERVICES MARKET IN U.K.: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 45 : STATISTICS FOR CVD IN DIFFERENT REGIONS OF THE WORLD, 2011
  • Table 46 : EXAMPLES OF STEM CELL POLICIES IN ASIAN COUNTRIES
  • Table 47 : STEM CELL MARKET: ASIA, HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 48 : STEM CELL THERAPY MARKET IN JAPAN: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 49 : STEM CELL RESEARCH AND SERVICES MARKET IN JAPAN: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 50 : STEM CELL CORD BLOOD SERVICES MARKET IN JAPAN: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 51 : STEM CELL THERAPY MARKET IN CHINA: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 52 : STEM CELL RESEARCH AND SERVICES MARKET IN CHINA: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 53 : STEM CELL CORD BLOOD SERVICES MARKET IN CHINA: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 54 : POTENTIAL CANDIDATES FOR STEM CELL THERAPY IN INDIA
  • Table 55 : STEM CELL THERAPY MARKET IN INDIA: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 56 : STEM CELL RESEARCH AND SERVICES MARKET IN INDIA: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 57 : STEM CELL CORD BLOOD SERVICES MARKET IN INDIA: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 58 : STEM CELL MARKET IN ROW: HISTORIC AND FORECAST DATA, THROUGH 2016
  • Table 59 : SIGNIFICANT STEM CELL RESEARCH PATENTS

List of Figures

  • Summary Figure : GLOBAL STEM CELL MARKET AND FORECASTS, 2010-2016
  • Figure 1 : EARLY DEVELOPMENT OF EMBRYO
Back to Top